Acotiamide market is demonstrating promising growth, driven by increasing prevalence of functional gastrointestinal disorders, particularly functional dyspepsia (FD). Acotiamide, a first-in-class prokinetic agent, plays a significant role in improving gastric motility and alleviating symptoms such as postprandial fullness, upper abdominal bloating, and early satiety. Functional dyspepsia remains a highly prevalent yet often underdiagnosed condition worldwide, significantly impacting patient quality of life. As awareness and diagnosis improve, demand for targeted therapies like acotiamide continues to rise. The drug’s unique mechanism—enhancing acetylcholine availability by inhibiting acetylcholinesterase positions it as an effective treatment option addressing the root cause of impaired gastric motility.
From a market standpoint, acotiamide operates within a niche but expanding gastrointestinal therapeutics segment. Japan remains a key market, where the drug (marketed as Acofide®) was first approved in 2013. Increasing interest from global pharmaceutical players is now driving expansion into new regions, including North America and Europe. However, challenges such as regulatory barriers, limited global approvals, and competition from alternative gastrointestinal therapies continue to influence market dynamics. Despite this, ongoing clinical research and strategic collaborations are expected to strengthen the drug’s global positioning. Distribution channels primarily include hospital pharmacies and gastroenterology clinics, with gradual expansion into broader outpatient settings as awareness increases.
Recent Industry Developments
In June 2024, Zeria Pharmaceutical Co., Ltd. and Agastra-Lab s.r.l. announced a landmark exclusive agreement to develop and commercialize acotiamide hydrochloride hydrate across Europe, the United States, and Canada. This strategic collaboration marks a significant step toward globalizing a therapy that has so far been primarily concentrated in Asian markets.
Acotiamide, the active ingredient in Acofide® 100 mg tablets, was originally discovered by Zeria and remains the first approved treatment specifically targeting functional dyspepsia. The agreement aims to accelerate regulatory pathways and improve patient access in Western markets, where FD remains a largely unmet clinical need. Industry experts, including Jan Tack, have emphasized the importance of advancing innovative therapies in this space.
In July 2023, acotiamide achieved a key regulatory milestone in Southeast Asia, receiving approval from the Thai Food and Drug Administration for import and sale. This approval highlights the growing regional acceptance of the drug and reinforces its clinical value in treating gastrointestinal motility disorders.
Further strengthening its clinical profile, in March 2026, researchers in Japan reported progress in a Phase II clinical trial evaluating acotiamide for esophagogastric junction outflow obstruction and related gastric motility disorders, including symptoms associated with diabetic gastroparesis. The study demonstrated favorable efficacy and safety outcomes, supporting the drug’s broader therapeutic potential beyond functional dyspepsia.
These developments underscore increasing global interest in acotiamide as a next-generation prokinetic therapy. Strategic partnerships, regulatory advancements, and expanding clinical research are collectively positioning the drug for wider adoption across international markets.
Despite existing challenges, including regulatory complexity and competitive treatment alternatives, the long-term outlook for acotiamide remains positive. Continued innovation and geographic expansion are expected to drive sustained growth, particularly as healthcare systems place greater emphasis on improving quality of life for patients with chronic gastrointestinal disorders.
